Summary of Study ST002011
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001275. The data can be accessed directly via it's Project DOI: 10.21228/M8WX21 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002011 |
| Study Title | The anticancer human mTOR inhibitor MLN0128/Sapanisertib with potent multistage in vitro antiplasmodium activity and in vivo antimalarial efficacy in a humanised mouse model is an inhibitor of multiple Plasmodium falciparum kinases. |
| Study Summary | Here we interrogated the in vitro metabolic effects of 6 drugs using ultra-high performance liquid chromatography mass-spectrometry (UHPLC-MS). The resulting metabolic fingerprints provide information on the parasite biochemical pathways affected by pharmacologic intervention and offer a critical blueprint for selecting and advancing lead compounds as next-generation antimalarial drugs. Our results reveal several distinctions between compounds with polypharmacological effects. |
| Institute | Pennsylvania State University |
| Department | Department of Biochemistry and Molecular Biology |
| Last Name | Llinas |
| First Name | Manuel |
| Address | W126 Millenium Science Complex, University Park, PA 16802 |
| manuel@psu.edu | |
| Phone | 814-867-3527 |
| Submit Date | 2021-12-08 |
| Raw Data Available | Yes |
| Analysis Type Detail | LC-MS |
| Release Date | 2022-11-02 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO002085 |
| Collection Summary: | Cells were pelleted and the media aspirated then a 1xPBS wash that was aspirated prior to quench and extraction. |
| Sample Type: | Pf infected RBCs |
